Related Experiment Video
Updated: Jul 20, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Antithrombotic therapy after left atrial appendage occlusion
Carmelo Raffo1, Antonio Greco1, Davide Capodanno1
1Cardiovascular Department, A.O.U. Policlinico "G. Rodolico - San Marco", University of Catania, Catania, Italy.
Expert Review of Cardiovascular Therapy
|March 28, 2025
Summary
Antithrombotic therapy after left atrial appendage occlusion (LAAO) is crucial for preventing device-related thrombosis. Direct oral anticoagulants (DOACs) appear most effective, balancing safety and efficacy in atrial fibrillation patients.
Area of Science:
- Cardiology
- Interventional Cardiology
- Thrombosis Management
Background:
- Left atrial appendage occlusion (LAAO) is used to reduce stroke risk in atrial fibrillation (AF) patients.
- LAAO procedures carry risks including bleeding, device embolization, leaks, and device-related thrombosis.
- Antithrombotic therapy is essential post-LAAO to prevent thrombosis due to blood-device contact.
Purpose of the Study:
- To review the rationale and implications of antithrombotic therapy following LAAO.
- To provide an overview of current evidence on various post-LAAO antithrombotic regimens.
- To define optimal antithrombotic strategies for LAAO patients.
Main Methods:
- Comprehensive literature search of PubMed, Web of Science, and Cochrane databases up to November 2024.
- Analysis of antithrombotic drugs including VKAs, DOACs, antiplatelet agents, and combinations.
- Evaluation of evolving strategies from high-intensity to simplified regimens.
Main Results:
- Current strategies aim for simplified antithrombotic approaches to promote device healing while minimizing bleeding risk.
- Direct oral anticoagulants (DOACs) show the lowest rates of thromboembolic events and major bleeding.
- Dual antiplatelet therapy (DAPT) is an option for patients intolerant to oral anticoagulants (OACs).
Conclusions:
- The optimal antithrombotic regimen post-LAAO is still debated, necessitating further randomized trials.
- DOACs are suggested as a preferred option due to their favorable risk-benefit profile.
- For high-bleeding-risk patients, single antiplatelet therapy or no antithrombotic therapy are viable alternatives.
Keywords:
Anticoagulationantiplatelet drugsantithrombotic therapyatrial fibrillationhigh bleeding riskleft atrial appendage occlusionsecondary preventionMore Related Videos
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:25Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...